PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations
https://www.facingourrisk.org/XRAY/niraparib-for-metastatic-prostate-cancer
Full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00757-9/fulltext
This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors. (posted 9/6/2022)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Is genetic testing recommended for me?
- Does my prostate cancer have homologous recombination deficiency (HRD)?
- Is my prostate cancer metastatic?
- Is PARP inhibitor therapy appropriate for me?
Open Clinical Trials
The following studies are looking at PARP inhibitors and similar agents for treating people with advanced prostate cancer.
- NCT04592237: Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer. This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (niraparib), and an immunotherapy agents (cetrelimab) works for treating people with a rare type of prostate cancer known as aggressive variant prostate cancer (AVPC).
- NCT05005728: XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. This study will look at the safety and clinical activity of the drug XmAb20717 alone or in combination with standard-of-care anticancer therapies in patients with metastatic castration-resistant prostate cancer who have been treated with at least 2 prior lines of treatment.
- NCT03317392: Studying the Medication Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis. This study is measuring the best dosage for and side effects of the drug combination olaparib and radium-223 to treat men with mCRPC that has spread to the bones.
Other clinical trials for people with prostate cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.